Beatrix
Beatrix Bahle, Oberhausen DE
Patent application number | Description | Published |
---|---|---|
20150353992 | RT-qPCR analysis of micro-dissected material from stained FFPET section - The present invention refers to a method for immuno-histochemical staining of a formalin-fixed, paraffin-embedded tissue section comprising the steps of a) providing a solid support, b) mounting the formalin-fixed, paraffin-embedded tissue section onto the solid support, c) removing the paraffin from the formalin-fixed, paraffin-embedded tissue section, d) heating the tissue section mounted on the solid support to retrieve epitopes at 50 to 70° C. for 12 to 24 h, and e) staining the tissue section mounted on the solid support, wherein at least step e) is performed in the presence of 0.5 to 3.0 M sodium chloride. The present invention further refers to a kit for performing the method. | 12-10-2015 |
Beatrix Bánkövi, Budapest HU
Patent application number | Description | Published |
---|---|---|
20130225695 | METHOD FOR PREPARATION OF AN EXCIPIENT SUITABLE FOR PHARMACEUTICAL USE - The present invention is related to a method for purifying diatomaceous earth wherein the natural colloidal structure of the material is retained, which comprises preparing a suspension of diatomaceous earth in a liquid wherein diatomaceous earth is insoluble, separating diatomaceous earth from the suspension, treating diatomaceous earth with an inorganic or organic acid, heat-treating the thus obtained product at a temperature not higher than 300° C., subjecting the product obtained to oxidative treatment and drying the purified product. | 08-29-2013 |
Beatrix Bánkövi, Budapest HU
Patent application number | Description | Published |
---|---|---|
20130225695 | METHOD FOR PREPARATION OF AN EXCIPIENT SUITABLE FOR PHARMACEUTICAL USE - The present invention is related to a method for purifying diatomaceous earth wherein the natural colloidal structure of the material is retained, which comprises preparing a suspension of diatomaceous earth in a liquid wherein diatomaceous earth is insoluble, separating diatomaceous earth from the suspension, treating diatomaceous earth with an inorganic or organic acid, heat-treating the thus obtained product at a temperature not higher than 300° C., subjecting the product obtained to oxidative treatment and drying the purified product. | 08-29-2013 |
Beatrix De Mathan, Paris FR
Patent application number | Description | Published |
---|---|---|
20080254789 | CELLULAR MOBILE COMMUNICATION NETWORK OPERATING METHOD AND SYSTEM - A cellular mobile communication network operating method comprises a step of calculating at least one adjustment frequency parameter representative of the adjustment frequency of at least one radio parameter associated with at least one network object and a step of using said at least one adjustment frequency parameter in at least one radio network optimization operation | 10-16-2008 |
Beatrix De Mathan, Velizy FR
Patent application number | Description | Published |
---|---|---|
20100182317 | Map display method used to enhance the display of a building by showing several levels of this building - This method is used to enhance the display of a building (SC) showing several levels (T, F | 07-22-2010 |
20100182342 | Map display method - The method is used to enlarge the display of a first portion of a map, without hiding a first peripheral portion of this map. This method includes detecting an event which appears in the first peripheral portion and defining a second portion to be enlarged, centered on the position of this event. A second peripheral zone associated with this second portion to be enlarged is defined and the second portion to be enlarged is displayed by applying respective enlargement ratios greater than 100% to at least some elements of that portion, so as to make the event more legible. The second peripheral portion is also displayed by applying at least to some elements of this portion respective enlargement ratios lower than 100% so as to save surface area to avoid hiding a portion of the map. | 07-22-2010 |
Beatrix Fyrnys, Muehlheim DE
Patent application number | Description | Published |
---|---|---|
20090136429 | Combination of Anticholinergics and Inhibitors of Phosphodiesterase Type 4 For The Treatment of Respiratory Disease - The present invention relates to a combination of an inhaled/oral PDE 4 inhibitor in combination with inhaled anticholinergic bronchodilators (muscarinic receptor antagonists), preferentially Roflumilast or AWD-12-281 and R, R-glycopyrrolate, for symptomatic or prophylactic treatment of respiratory diseases, especially those accompanied by obstruction or inflammation such as chronic obstructive pulmonary disease (COPD) or asthma. It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the Novolizer®. | 05-28-2009 |
Beatrix Kottwitz, Erkrath DE
Patent application number | Description | Published |
---|---|---|
20090120555 | Novel amylolytic enzyme extracted from Bacillus sp. A 7-7 (DSM 12368) and washing and cleaning agents containing this novel amylolytic enzyme - The invention relates to a novel amylolytic enzyme extracted from the microorganism | 05-14-2009 |
20100298198 | Alkaline Proteases and Detergents and Cleaners Comprising These Alkaline Proteases - The present application relates to two novel proteases (SEQ ID NO: 4 and 7) which are similar to one another, whose DNA was obtained from soil samples, and C-terminally deleted, likewise proteolytically active fragments thereof (SEQ ID NO: 5 and 8), all alkaline proteases similar at least to 90% to SEQ ID NO: 4 or to 87.5% to SEQ ID NO: 7, and those which can be summarized under a consensus sequence (SEQ ID NO: 9) derived from SEQ ID NO: 4 and 7. Furthermore, it relates to all nucleic acids which have a homology of at least 85% identity to the associated nucleic acids (SEQ ID NO: 3 and 6) or the fragments concerned. Furthermore, it defines technical possibilities of use for these proteases and especially describes their use in detergents and cleaners. | 11-25-2010 |
Beatrix Loehner, West Yorkshire GB
Patent application number | Description | Published |
---|---|---|
20090029168 | Reverse Phase Hydrophilic Polymers and Their Use in Water-Expandable Elastomeric Compositions - Water-swellable compositions, dispersions and polymer microparticles for their preparation as well as their manufactures and uses are described. | 01-29-2009 |
20110042613 | SWELLABLE COMPOSITIONS - Water-swellable compositions, dispersions and hydrophilic cross-linked polymer microparticles for their preparation as well as their manufactures and uses are described. The polymer microparticles are formed from a monomer blend comprising sulphonic monomer, nonionic monomer and optionally other monomers and have a volume mean average size of below 20 microns. The compositions are useful in applications, such as seals and other water blocking applications. | 02-24-2011 |
Beatrix Srelte Ludwig, Wulfrath DE
Patent application number | Description | Published |
---|---|---|
20130261064 | N-CARBOXYALKYL-AURISTATIN AND THE USE THEREOF - The present application relates to new derivatives of monomethylauristatin F, substituted on the N terminus by a carboxyalkyl group, processes for preparing these derivatives, their use for the treatment and/or prevention of diseases and to produce medication for the treatment and/or prevention of diseases, particularly hyperproliferative and/or angiogenic disorders such as cancer disorders, for example. Such treatments can occur as monotherapies or in combination with other medication or further therapeutic measures. | 10-03-2013 |
Beatrix Stelet-Ludwig, Wulfrath DE
Patent application number | Description | Published |
---|---|---|
20150148298 | N-CARBOXYALKYL-AURISTATIN AND USE THEREOF - The present application relates to new derivatives of monomethylauristatin F, substituted on the N terminus by a carboxyalkyl group, processes for preparing these derivatives, their use for the treatment and/or prevention of diseases and to produce medication for the treatment and/or prevention of diseases, particularly hyperproliferative and/or angiogenic disorders such as cancer disorders, for example. Such treatments can occur as monotherapies or in combination with other medication or further therapeutic measures. | 05-28-2015 |
Beatrix Stelte-Ludwig, Wülfrath DE
Patent application number | Description | Published |
---|---|---|
20080214654 | Substituted Benzyloxy-Phenylmethylamide Derivatives - The present invention relates to novel substituted benzyloxy-phenylmethylamide derivatives, processes for their preparation, and their use in medicaments, especially for the prophylaxis and treatment of diseases associated with Cold Menthol Receptor 1 (CMR-1) activity, in particular for the treatment of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor oeractivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD). | 09-04-2008 |
20090221573 | Use of Activators of Soluble Guanylate Cyclase for Promoting Wound Healing - The present invention relates to a method for promoting wound healing by administering one or more compounds identified in the claims, and to pharmaceutical compositions containing such compounds. | 09-03-2009 |
20120321619 | ANTI-C4.4A ANTIBODIES AND USES THEREOF - The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 29 kDa C4.4a polypeptide, which is over expressed in several tumors, e.g. lung, colorectal, pancreas, prostate, renal and breast cancer. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of C4.4a in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. | 12-20-2012 |
20130066055 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF - The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures. | 03-14-2013 |
20130122024 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF - The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target mesothelin, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures. | 05-16-2013 |
20130157960 | NOVEL AURISTATIN DERIVATIVES AND USE THEREOF - The present application relates to novel derivatives of monomethylauristatin F, to processes for preparing these derivatives, to the use of these derivatives for treating and/or preventing diseases, and also to the use of these derivatives for preparing medicaments for treating and/or preventing diseases, more particularly hyperproliferative and/or angiogenic disorders such as, for example, cancerous disorders. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures. | 06-20-2013 |
20140080763 | N-CARBOXYALKYLAURISTATINS AND USE THEREOF - The present application relates to new derivatives, substituted on the N terminus by a carboxyalkyl group, of monomethylauristatin E and monomethylauristatin F, to processes for preparing these derivatives, to the use of these derivatives for treating and/or preventing diseases, and to the use of these derivatives for producing medicaments for treating and/or preventing diseases, more particularly hyperproliferative and/or angiogenic disorders such as cancer disorders, for example. Such treatments may be applied as a monotherapy or else in combination with other medicaments or further therapeutic measures. | 03-20-2014 |
20140127240 | Novel Binder-Drug Conjugates (ADCs) and Use of Same - The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures. | 05-08-2014 |
20140322220 | Anti-FGFR2 Antibodies and Uses Thereof - The present invention provides antibodies, or antigen-binding antibody fragments thereof, or variants thereof which reduce the cell surface expression of FGFR2 after binding to FGFR2 in both cells overexpressing FGFR2 and cells expressing mutated FGFR2. Also provided are antibody-based therapies for FGFR2-related diseases or conditions such as cancer. Antibodies of the invention also can be used in the diagnostics field. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. | 10-30-2014 |
20150030618 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF - The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures. | 01-29-2015 |
Beatrix Stelte-Ludwig DE
Patent application number | Description | Published |
---|---|---|
20130095123 | New binder-drug conjugates (ADCs) and use thereof - The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures. | 04-18-2013 |
Beatrix Stelte-Ludwig, Wuelfrath DE
Patent application number | Description | Published |
---|---|---|
20150246136 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME - The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures. | 09-03-2015 |
Beatrix Stelte-Ludwig, Wülfrath DE
Patent application number | Description | Published |
---|---|---|
20090221573 | Use of Activators of Soluble Guanylate Cyclase for Promoting Wound Healing - The present invention relates to a method for promoting wound healing by administering one or more compounds identified in the claims, and to pharmaceutical compositions containing such compounds. | 09-03-2009 |
20130122024 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF - The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target mesothelin, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures. | 05-16-2013 |
Beatrix Stelte-Luowig, Wulfrath DE
Patent application number | Description | Published |
---|---|---|
20150023989 | NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF - The present application relates to new antibody drug conjugates (ADCs) of N,N dialkylauristatins directed against the target FGFR2, drug metabolites of said ADCs, a method for producing said ADCs, the use of said ADCs for the treatment and/or prevention of illnesses as well as the use of said ADCs for producing pharmaceuticals for the treatment and/or prevention of illnesses, particularly of hyperproliferative and/or angiogenic diseases such as carcinosis. Such treatments can be carried out as monotherapy or in combination with other pharmaceuticals or additional therapeutic measures. | 01-22-2015 |
Beatrix Ueberheide, New York, NY US
Patent application number | Description | Published |
---|---|---|
20160089416 | METHOD OF TREATING CANCER - This disclosure pertains to a method of treating liver cancer using a peptide based on venom from a | 03-31-2016 |
Beatrix Vom Bruch, Herten DE
Patent application number | Description | Published |
---|---|---|
20140288207 | CURABLE COMPOSITION HAVING CONSTITUENTS WHICH LIBERATE ALCOHOL DURING CURING - The present invention relates to a curable composition comprising at least one nonexclusively terminally alkoxysilylated alkoxylation product and at least one curing catalyst, which is characterized in that the nonexclusively terminally alkoxysilylated alkoxylation product is a prepolymer having an average of between 2.0 and 8.0 ethoxysilyl functions per prepolymer, and to sealants and/or adhesives comprising this curable composition, and to the use of the curable composition or the sealant and adhesive. | 09-25-2014 |
Beatrix Wagner, Lorrach DE
Patent application number | Description | Published |
---|---|---|
20080293731 | Organic Compounds - The present invention relates to 1-aza-bicycloalkyl derivatives of Formula (I) | 11-27-2008 |
20100179160 | ORGANIC COMPOUNDS - The present invention relates to 1-aza-bicycloalkyl derivatives of Formula (I) wherein the substituents are as defined in the specification and to processes for their production to pharmaceutical compositions comprising them and to their use in the manufacture of a medicament for the treatment and/or delay of progression of psychotic and nemodegenerative disorders. | 07-15-2010 |
20120022074 | ORGANIC COMPOUNDS - The present invention relates to 1-aza-bicycloalkyl derivatives of Formula (I) wherein the substituents are as defined in the specification and to processes for their production to pharmaceutical compositions comprising them and to their use in the manufacture of a medicament for the treatment and/or delay of progression of psychotic and nemodegenerative disorders. | 01-26-2012 |
20140113908 | [(1H-INDOL-5-YL) - HETEROARYLOXY] - (1-AZA-BICYCLO [3.3.1] NONANES AS CHOLINERGIC LIGANDS OF THE N-ACHR FOR THE TREATMENT OF PSYCHOTIC AND NEURODEGENRATIVE DISORDERS - The present invention relates to 1-aza-bicycloalkyl derivatives of Formula (I) wherein the substituents are as defined in the specification and to processes for their production to pharmaceutical compositions comprising them and to their use in the manufacture of a medicament for the treatment and/or delay of progression of psychotic and nemodegenerative disorders. | 04-24-2014 |